Literature DB >> 3319456

Laboratory assessment of inflammatory bowel disease.

I T Beck1.   

Abstract

Presently there are no specific laboratory tests to diagnose inflammatory bowel disease (IBD). Nonspecific tests to differentiate diarrhea due to mucosal injury from that occurring in patients with normal bowel mucosa (eg, fecal occult blood, leukocytes, etc) are not helpful. Tests to exclude infections agents are very important, since the clinical and radiological appearance of these may mimic IBD, and patients with IBD may suffer from superinfection. There are no laboratory tests which can differentiate Crohn's colitis from ulcerative colitis (UC). The tests used in the assessment and management of severely ill patients (Hgb, WBC, electrolytes, etc) are important, since abnormalities need to be corrected on an ongoing basis. The tests used to assess nutritional status are of little clinical value, since "clinical assessment" is as good as the laboratory assessment. Estimation of disease activity by tests is rarely better than the judgment of the clinician. Workup for malabsorption in Crohn's disease and the assessment of absorptive capacity of the terminal ileum are important for proper planning of management. Laboratory tests are also useful in clarifying the nature of some complications (eg, anemias and joint diseases).

Entities:  

Mesh:

Year:  1987        PMID: 3319456     DOI: 10.1007/BF01312461

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  110 in total

1.  Serum lysozyme in Crohn's disease. A useful index of disease activity.

Authors:  K R Falchuk; J L Perrotto; K J Isselbacher
Journal:  Gastroenterology       Date:  1975-10       Impact factor: 22.682

2.  Evaluation of 200 D(plus)-xylose blood level time curves as an index of intestinal absorption.

Authors:  I T BECK; S RONA; R D McKENNA; D S KAHN
Journal:  Am J Dig Dis       Date:  1962-10

3.  Exchangeable potassium as a parameter of body composition.

Authors:  P J TALSO; C E MILLER; A J CARBALLO; I VASQUEZ
Journal:  Metabolism       Date:  1960-05       Impact factor: 8.694

4.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

5.  Gases produced by human intestinal microflora.

Authors:  D H Calloway; D J Colasito; R D Mathews
Journal:  Nature       Date:  1966-12-10       Impact factor: 49.962

6.  Serum lysozyme in Crohn's disease and ulcerative colitis.

Authors:  K R Falchuk; J L Perrotto; K J Isselbacher
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

7.  Undernutrition in Crohn's disease: an anthropometric assessment.

Authors:  A D Harries; J Rhodes
Journal:  Clin Nutr       Date:  1985-05       Impact factor: 7.324

8.  Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG.

Authors:  K B Jensen; S Jarnum; G Koudahl; M Kristensen
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

9.  Inhibition of folate enzymes by sulfasalazine.

Authors:  J Selhub; G J Dhar; I H Rosenberg
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

10.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

View more
  6 in total

1.  Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis.

Authors:  G D'Argenio; V Cosenza; G Riegler; N Della Valle; F Deritis; G Mazzacca
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

2.  Clinical activity assessment in inflammatory bowel disease.

Authors:  J W Singleton
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

3.  Ulcerative colitis: an overview.

Authors:  A Archambault
Journal:  Can Fam Physician       Date:  1990-02       Impact factor: 3.275

4.  Fecal lysozyme in assessment of disease activity in inflammatory bowel disease.

Authors:  A van der Sluys Veer; J Brouwer; I Biemond; G E Bohbouth; H W Verspaget; C B Lamers
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

5.  Microalbuminuria in inflammatory bowel disease.

Authors:  N Mahmud; J Stinson; M A O'Connell; T J Mantle; P W Keeling; J Feely; D G Weir; D Kelleher
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

6.  Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission.

Authors:  C A M Wegh; N M de Roos; R Hovenier; J Meijerink; I Besseling-van der Vaart; S van Hemert; B J M Witteman
Journal:  J Nutr Metab       Date:  2019-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.